16 May 2016 - An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

The TGA approved Repatha for use as an adjunct to diet and exercise in certain patients with primary hypercholesterolaemia and homozygous familial hypercholesterolaemia on 9 December 2015.

For more details, go to: http://www.tga.gov.au/sites/default/files/auspar-_evolocumab-rch-160503.pdf